学术周报 · IF≥10 或专科旗舰刊

消化内科领域文献阅读汇编

2026年第47周 (2026-11-20) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
收录论文
20
临床研究
9
基础研究
11
IF≥20
7
IF 10-20
11
子领域
11
期刊种类
15
数据日期
2026-11-20

★本周 Top 10 高影响力文献

#论文期刊IF
1Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy.Nature medicineIF 52.5
2Checkpoint Inhibition during primary hepatitis E virus infection alters memory development of virus-...Journal of hepatologyIF 40.1
3Circulating CXCR6+PD-1+ CD8 T cells are associated with liver inflammation and disease severity in h...Clinical and molecular hepatologyIF 21.7
4Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Cirrhosis: A Network Meta-analysis o...Clinical and molecular hepatologyIF 21.7
5A Novel Competing-Risk Model Integrating Systemic Inflammation to Predict Acute-on-Chronic Liver Fai...Clinical and molecular hepatologyIF 21.7
6KASL Consensus Statement for Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatohepat...Clinical and molecular hepatologyIF 21.7
7From bench to bedside: 60-year development of adenine nucleoside- and nucleotide-based antiviral dru...Clinical microbiology reviewsIF 20.7
8The microbial glycan landscape instructs natural antibody repertoires.Trends in microbiologyIF 18.7
9Exercise-induced lactylation in WDR41 initiates autophagy and improves fatty liver diseases.AutophagyIF 18.6
10Prime-LS: a cryoprotectant-free, lyophilized MSC-secretome conferring protection against acute exper...Trends in biotechnologyIF 16.6

Ŧ期刊分布统计

期刊篇数IF
Clinical and molecular hepatology4IF 21.7
Alimentary pharmacology & therapeutics2IF 6.8
Biosensors & bioelectronics2IF 11.8
Nature medicine1IF 52.5
Journal of hepatology1IF 40.1
Endoscopy1IF 11.8
Trends in biotechnology1IF 16.6
IEEE transactions on cybernetics1IF 11.3
Clinical microbiology reviews1IF 20.7
Advanced healthcare materials1IF 11.0

1炎症性肠病/IBD (5篇)

临床研究 (1篇)

Alimentary pharmacology & therapeutics IF 6.8 2026-11-13 PMID: 43023622
Healthcare contributes 4.4%-5% of global greenhouse gas emissions. Inflammatory bowel disease (IBD) requires repeated diagnostic investigations throughout a patient's lifetime, adding to healthcare's environmental footprint. However, the carbon footprint and cost of IBD diagnostic modalities have not been systematically compared AIMS: To quantify per-procedure emissions and relative costs of IBD diagnostics and model potential savings from intestinal ultrasound (IUS) when clinically appropriate. This prospective observational study quantified operational emissions at AIG Hospitals, Hyderabad, India, during December 2025 using the Greenhouse Gas Protocol, institutional data, and a three-state power model. Procedures included laboratory tests (27,330), colonoscopy/enteroscopy (1290), CT (1520), MRI (589), and IUS (923). Sensitivity analyses were performed to assess the robustness of emission estimates by varying assumptions regarding infrastructure allocation, equipment power consumption, procedure volumes, and electricity grid emission factors. Emissions ranged from 0.462 kg CO2e per laboratory test to 21.25 kg CO2e per MRI. IUS (0.850 kg CO2e) was the lowest-carbon imaging modality, with 4.6-, 6.8-, and 25.0-fold lower emissions than colonoscopy/enteroscopy, CT, and MRI, respectively. Cross-sectional imaging contributed 53.7% of total emissions (39,778 kg CO2e), versus 2.0% for IUS. Costs increased with emissions. When clinically appropriate, substituting IUS for colonoscopy or MR enterography could reduce per-procedure emissions by 78.0% and 96.0%, respectively. Carbon emissions and cost rise together across IBD diagnostics; when clinically appropriate, IUS is the lowest-carbon, lowest-cost imaging modality. Patient-level studies are needed to confirm modelled savings. ClinicalTrials.gov NCT07431983.
中文摘要:医疗保健贡献了全球4.4%至5%的温室气体排放。炎症性肠病(IBD)患者在一生中需要反复进行诊断检查,这增加了医疗环境的碳足迹。然而,IBD诊断方法的碳足迹和成本尚未得到系统比较。本研究旨在量化IBD诊断方法的单次操作排放量及相对成本,并模拟在临床适用情况下使用肠道超声(IUS)的潜在节约效果。这是一项前瞻性观察研究,于2025年12月在印度海德拉巴AIG医院利用温室气体协议、机构数据和三态功率模型量化了运营排放。纳入的程序包括实验室检测(27,330例)、结肠镜/小肠镜(1,290例)、CT(1,520例)、MRI(589例)和IUS(923例)。通过改变关于基础设施分配、设备功耗、程序体积和电网排放因子的假设,进行了敏感性分析以评估排放量估计的稳健性。排放量范围从每例实验室检测0.462千克二氧化碳当量到每例MRI 21.25千克二氧化碳当量。IUS(0.850千克二氧化碳当量)是碳足迹最低的成像方式,其排放量分别比结肠镜/小肠镜、CT和MRI低4.6倍、6.8倍和25.0倍。横断面成像贡献了总排放量的53.7%(39,778千克二氧化碳当量),而IUS仅占2.0%。成本随排放量增加而上升。在临床适用的情况下,用IUS替代结肠镜或MR小肠造影可使单次操作排放量分别减少78.0%和96.0%。IBD诊断的碳排放和成本同步上升;在临床适用时,IUS是碳足迹最低且成本最低的成像方式。需要患者层面的研究来证实模型计算的节约效果。ClinicalTrials.gov注册号为NCT07431983。

基础研究 (4篇)

Trends in biotechnology IF 16.6 2026-11-17 PMID: 43045542
Ulcerative colitis (UC) is a chronic, immune-mediated disorder characterized by recurrent mucosal inflammation and epithelial damage. Its incidence is rising, while current therapies fail to achieve durable remission due to limited efficacy or adverse effects. Cell-free approaches based on the mesenchymal stromal cell (MSC) secretome offer an alternative with improved safety and scalability. In this study, we present Prime-LS, an excipient-free, off-the-shelf MSC-secretome biologic that retains immunomodulatory activity without cryoprotectants. Prime-LS preserves soluble immunomodulatory mediators and extracellular vesicle populations with characteristic surface markers and vesicular morphology following lyophilization and reconstitution, while forming a homogeneous formulation without visible precipitation or detectable aggregate formation. In vitro, Prime-LS suppressed proliferation of peripheral blood mononuclear cells, while in vivo subcutaneous dosing in a murine colitis model prevented disease onset, preserved mucosal integrity, and normalized inflammation. Together, these findings support Prime-LS as a stable, functionally preserved MSC-secretome formulation with potential for further translational development in UC and other immune-mediated diseases.
中文摘要:溃疡性结肠炎(UC)是一种慢性免疫介导性疾病,以复发性黏膜炎症和上皮损伤为特征。其发病率不断上升,而现有疗法因疗效有限或不良反应无法实现持久缓解。基于间充质干细胞(MSC)分泌组的无细胞方法提供了安全性与可扩展性更优的替代方案。本研究提出Prime-LS,这是一种不含辅料、即用的MSC分泌组生物制剂,在不使用冷冻保护剂的情况下仍保留免疫调节活性。冻干及复溶后,Prime-LS保留了可溶性免疫调节介质和具有特征性表面标志物及囊泡形态的细胞外囊泡群,形成均一制剂且无可见沉淀或可检测到的聚集体形成。体外实验中,Prime-LS抑制了外周血单个核细胞的增殖;体内在小鼠结肠炎模型中皮下给药可预防疾病发生、维持黏膜完整性并恢复正常炎症水平。综上所述,这些发现支持Prime-LS作为一种稳定且功能保留的MSC分泌组制剂,具有在UC及其他免疫介导性疾病中进一步转化开发的潜力。
Advanced healthcare materials IF 11.0 2026-11-16 PMID: 43036905
Mucosal healing is a key therapeutic goal in inflammatory bowel disease (IBD), which is characterized by mucosal lesions in the gastrointestinal tract. For IBD drug development, it is important to identify multiple compounds with strong effects on mucosal injury and different mechanisms of action. Here, we established an intestinal organoid-based assay to evaluate cytokine-induced inflammatory and epithelial stress responses. We also developed an intestinal microphysiological system (intestinal MPS)-based assay for quantitative evaluation of cytokine-induced changes in mucosal architecture. By integrating these assays, we constructed a multi-stage screening platform to identify candidate compounds that suppress inflammatory responses and preserve mucosal architecture. Tofacitinib, an approved IBD drug, showed positive effects in these assays, supporting the relevance of this platform. Although organoid-based screening identified pimitespib as a candidate compound, pimitespib did not improve mucosal architecture in the intestinal MPS. Consistently, pimitespib failed to restore mucosal morphology in an IBD mouse model. These findings suggest that combining intestinal organoids with an intestinal MPS may help identify candidate compounds that suppress inflammatory responses while preserving mucosal architecture.
中文摘要:黏膜愈合是炎症性肠病的核心治疗目标,该病以胃肠道黏膜病变为特征。在炎症性肠病药物研发中,识别对黏膜损伤具有强效且作用机制不同的多种化合物至关重要。本研究建立了基于肠道类器官的检测方法,用于评估细胞因子诱导的炎症和上皮应激反应。同时开发了基于肠道微生理系统的检测方法,用于定量评估细胞因子诱导的黏膜结构变化。整合上述检测手段构建了多阶段筛选平台,旨在识别能抑制炎症反应并维持黏膜结构的候选化合物。获批的炎症性肠病药物托法替汀在该平台中显示积极效果,验证了平台的适用性。尽管基于类器官的筛选将pimitespib鉴定为候选化合物,但其在肠道微生理系统中未能改善黏膜结构。与此一致,pimitespib在炎症性肠病小鼠模型中也未能恢复黏膜形态。这些发现表明,结合肠道类器官与肠道微生理系统有助于识别既能抑制炎症反应又能维持黏膜结构的候选化合物。
eGastroenterology IF 10.5 2026 PMID: 43047989
Intestinal dysbiosis, an imbalance in gut microbial composition and host-microbiome interaction, has been linked to various conditions and disorders. Although characterised by multiple features, such as reduced microbial diversity and bacterial load, as well as an underrepresentation of beneficial microorganisms and an overrepresentation of pathobionts, an exact definition remains elusive. Whether all dysbiotic individuals share similar microbial composition and host properties is currently unclear. Here, we analysed 4500 faecal microbiomes from five cohorts, spanning various pathologies and degrees of health, collected and processed using identical laboratory and bioinformatics protocols. Focusing on Bacteroides 2 (Bact2) microbiome profiles (n=754) as representatives of dysbiosis, we studied the dysbiotic landscape of microbiota composition and associated host variables. Two of the three identified Bact2 areas were clearly biologically defined, showing distinct host properties in transit time and inflammatory tone. The inflammatory area exhibits established dysbiosis properties, such as strongly decreased microbial load and richness and increased pathobiont prevalence, and is found in patients with active inflammatory bowel disease and increased faecal calprotectin values. In addition, a second, novel dysbiotic profile was identified, characterised by slower intestinal transit and an increase in slow-growing bacteria, while still exhibiting dysbiotic features compared with eubiotic enterotypes. Both areas are associated with recent antibiotic use yet they manifest in different compositions due to other drivers. Together, these results show significant variation in composition and host factors within the dysbiosis landscape, with potential implications for the interpretation of microbiome-based diagnostics and future microbiome-modulation studies.
中文摘要:肠道菌群失调是肠道微生物组成及宿主与微生物相互作用失衡的状态,已证实与多种疾病和紊乱相关。尽管其特征包括微生物多样性及细菌负荷降低、有益微生物代表性不足及致病菌过度表达等,但确切定义仍不明确。目前尚不清楚所有菌群失调个体是否共享相似的微生物组成及宿主特征。本研究分析了来自五个队列的4500个粪便微生物组样本,涵盖不同病理状态及健康程度,并采用统一的实验室与生物信息学流程进行处理。以Bacteroides 2(Bact2)微生物组谱系(n=754)作为菌群失调的代表,我们研究了微生物组成及关联宿主变量的失调景观。在识别出的三个Bact2区域中,有两个具有明确的生物学定义,表现出不同的宿主特征,涉及肠道转运时间及炎症水平。炎症区域展现出既定的菌群失调特征,包括微生物负荷和丰富度显著降低以及致病菌流行率增加,主要见于活动性炎症性肠病患者及粪便钙卫蛋白值升高的个体。此外,研究还鉴定出第二种新型失调谱系,其特征为肠道转运速度减慢及慢生长细菌增加,尽管与正常菌群型相比仍表现出失调特征。这两个区域均与近期抗生素使用相关,但因其他驱动因素而呈现出不同的组成。综上所述,这些结果表明菌群失调景观在组成和宿主因素方面存在显著差异,对基于微生物组的诊断解释及未来微生物组调节研究具有潜在意义。
Trends in microbiology IF 18.7 2026-11-13 PMID: 43026055
The human gut mucosa presents a dynamic glycan landscape, built from host, microbial, and dietary carbohydrates and remodeled throughout life. Gut microbes deploy a vast repertoire of surface glycans that drive immune evasion, lectin signaling, immunomodulation, and ecological competition. Natural antiglycan antibodies, we argue, are not fixed baseline features of humoral immunity but are structured readouts of glycan exposure, founded during early-life colonization and revised thereafter by diet, infection, vaccination, and inflammation. We trace how microbial glycan diversity arises, how specific glycan classes instruct antibody specificity, and how disrupting this glycan-immune dialog drives inflammatory bowel disease, xenosialitis, infection, and allergy. Reframing natural antibodies as ecologically instructed rather than genetically preset identifies the glycan landscape as a lifelong determinant of immune calibration.
中文摘要:人体肠道黏膜呈现出动态的糖景观,由宿主、微生物和膳食碳水化合物构成并在整个生命周期中不断重塑。肠道微生物利用庞大的表面糖库来驱动免疫逃逸、凝集素信号传导、免疫调节及生态竞争。我们认为天然抗糖抗体并非体液免疫中固定的基线特征,而是糖暴露的结构化读数,其形成于生命早期的定植阶段,并在此后受饮食、感染、疫苗接种和炎症的影响而不断修订。我们追溯了微生物糖多样性的产生机制、特定糖类如何指导抗体特异性,以及破坏这种糖-免疫对话如何导致炎症性肠病、异种凝集素炎、感染和过敏。将天然抗体重新定义为生态指导而非基因预设,确立了糖景观作为终身免疫校准决定因素的地位。

2肝硬化/门脉高压 (3篇)

临床研究 (3篇)

Alimentary pharmacology & therapeutics IF 6.8 2026-11-17 PMID: 43045657
Decompensated cirrhosis has traditionally been considered irreversible. However, evidence shows that patients who achieve control or cure of the underlying liver disease aetiology can experience substantial clinical improvement, termed 'cirrhosis recompensation', formally defined by Baveno VII and further modified during Baveno VIII. This review synthesizes current knowledge on the pathophysiology, predictors, aetiology-specific outcomes, clinical implications and trial design considerations relevant to recompensation. We conducted a narrative review synthesizing data across six domains: pathophysiology of decompensation and recompensation; predictors of recompensation; prevalence and prognostic impact by aetiology; unresolved controversies in definition; clinical implications, including medication de-escalation, transplant delisting and hepatocellular carcinoma (HCC) surveillance; and methodological considerations for clinical trial design. Recompensation occurs in an estimated 35% of patients with decompensated cirrhosis and is associated with reduced liver-related mortality, though rates vary substantially by aetiology. Proposed mechanisms include reduced portal pressure, restored gut barrier integrity and possible fibrosis regression. Despite improved outcomes, HCC risk and, in some patients, portal hypertension persist, warranting ongoing surveillance. Some aspects of the definition remain unresolved, including uncertain applicability to etiologies lacking a clear curative therapy. As a trial endpoint, recompensation is clinically meaningful and sufficiently prevalent, though it requires appropriate handling of competing risks and consideration of multi-state modelling and outcome-ranking approaches. Cirrhosis recompensation represents a paradigm shift in the understanding and management of decompensated liver disease. Future work should focus on validating recompensation criteria across diverse etiologies, clarifying underlying mechanisms and durability and establishing standardized methodological frameworks for incorporating recompensation into clinical trial design.
中文摘要:失代偿性肝硬化传统上被认为不可逆转,但证据表明,实现基础肝病病因控制或治愈的患者可出现显著临床改善,称为「肝硬化再代偿」,其由Baveno VII正式定义并在Baveno VIII中进一步修正。本综述综合了关于再代偿的病理生理学、预测因素、病因特异性结局、临床意义及试验设计考虑因素的当前知识。我们进行了叙述性综述,综合了六个领域的数据:失代偿与再代偿的病理生理学;再代偿的预测因素;按病因分类的患病率及预后影响;定义中未解决的争议;临床意义(包括药物降阶梯、肝移植除名及肝细胞癌HCC监测);以及临床试验设计的Methodological考虑。估计35%的失代偿性肝硬化患者发生再代偿,这与肝脏相关死亡率降低相关,尽管发生率因病因而异。提出的机制包括门静脉压力降低、肠道屏障完整性恢复及可能的纤维化逆转。尽管预后改善,但HCC风险及部分患者的门静脉高压仍然存在,需持续监测。定义的一些方面仍未解决,包括对缺乏明确治愈疗法的病因的适用性不确定。作为试验终点,再代偿具有临床意义且患病率足够高,但需适当处理竞争风险并考虑多状态建模及结果排序方法。肝硬化再代偿代表了理解和管理失代偿性肝病的范式转变。未来工作应侧重于在不同病因中验证再代偿标准、阐明潜在机制及其持久性,并建立将再代偿纳入临床试验设计的标准化方法框架。
Clinical and molecular hepatology IF 21.7 2026-11-17 PMID: 43041059
The relative efficacy of antibiotic prophylaxis for spontaneous bacterial peritonitis (SBP) remains uncertain. We performed a network meta-analysis of randomized controlled trials (RCTs) of prophylactic antibiotic regimens. We searched PubMed, Embase, Cochrane Library, and Web of Science for RCTs of antibiotic prophylaxis in cirrhosis. Primary outcomes were SBP incidence and all-cause mortality. Twenty-eight RCTs were included. For all-cause mortality, the network was coherent, and rifaximin (risk ratio [RR], 0.50; 95% confidence interval [CI], 0.33-0.76), trimethoprim-sulfamethoxazole (RR, 0.48; 95% CI, 0.25-0.90), norfloxacin plus rifaximin (RR, 0.38; 95% CI, 0.17-0.86), and norfloxacin (RR, 0.69; 95% CI, 0.52-0.91) were associated with lower mortality. For SBP incidence, node-splitting revealed significant incoherence for rifaximin (P=0.015): direct evidence from five double-blind placebo-controlled trials (RR, 0.58; 95% CI, 0.27-1.25) diverged from indirect evidence via open-label head-to-head trials (RR, 0.15; 95% CI, 0.07-0.33). In primary prophylaxis, rifaximin (RR, 0.41; 95% CI, 0.22-0.76), norfloxacin (RR, 0.41; 95% CI, 0.22-0.78), and norfloxacin plus rifaximin (RR, 0.28; 95% CI, 0.10-0.75) reduced SBP incidence. In secondary prophylaxis, rifaximin showed the largest reduction in recurrence (RR, 0.08; 95% CI, 0.02-0.29), anchored on one placebo-controlled trial. The preventive effect attenuated with calendar year for SBP (ratio of risk ratios, 1.038 per year; 95% CI, 1.008-1.068; P=0.012) but not for mortality. Antibiotic prophylaxis is associated with lower all-cause mortality in cirrhosis with ascites, with rifaximin showing the most consistent survival benefit. However, its SBP estimate was not reproduced in blinded placebo-controlled trials, and the preventive effect against SBP attenuated over time.
中文摘要:自发性细菌性腹膜炎(SBP)的抗生素预防相对疗效仍不确定。我们对肝硬化患者预防性抗生素方案的随机对照试验(RCT)进行了网络Meta分析。检索PubMed、Embase、Cochrane图书馆和Web of Science中关于肝硬化抗生素预防的RCT。主要结局为SBP发病率和全因死亡率。纳入28项RCT。就全因死亡率而言,网络一致性良好,利福昔明(风险比[RR] 0.50;95%置信区间[CI] 0.33-0.76)、复方新诺明(RR 0.48;95% CI 0.25-0.90)、诺氟沙星联合利福昔明(RR 0.38;95% CI 0.17-0.86)和诺氟沙星(RR 0.69;95% CI 0.52-0.91)均与死亡率降低相关。就SBP发病率而言,节点拆分显示利福昔明存在显著不一致性(P=0.015):来自五项双盲安慰剂对照试验的直接证据(RR 0.58;95% CI 0.27-1.25)与通过开放标签头对头试验获得的间接证据(RR 0.15;95% CI 0.07-0.33)存在分歧。在一级预防中,利福昔明(RR 0.41;95% CI 0.22-0.76)、诺氟沙星(RR 0.41;95% CI 0.22-0.78)和诺氟沙星联合利福昔明(RR 0.28;95% CI 0.10-0.75)降低了SBP发病率。在二级预防中,利福昔明显示出最大的复发降低效果(RR 0.08;95% CI 0.02-0.29),基于一项安慰剂对照试验。SBP的预防效果随日历年份减弱(风险比比率每年1.038;95% CI 1.008-1.068;P=0.012),但死亡率无此变化。肝硬化腹水患者的抗生素预防与全因死亡率降低相关,利福昔明显示出最一致的生存获益。然而,其SBP估计值未在盲法安慰剂对照试验中得到复现,且对SBP的预防效果随时间减弱。
Clinical and molecular hepatology IF 21.7 2026-11-17 PMID: 43041054
Absolute risk of acute-on-chronic liver failure (ACLF) can be overestimated when the hazards of competing events, such as liver transplantation (LT) or death without ACLF, are not incorporated. We developed and validated a novel competing-risk-based model integrating systemic inflammation to predict ACLF development. The derivation cohort comprised 1,146 patients with acute decompensation of cirrhosis from the prospective, multicenter Korean Acute-on-Chronic Liver Failure (KACLiF) cohort. External validation used a retrospective 1,104-patient cohort. The study followed the TRIPOD+AI reporting guidelines and applied a Fine-Gray subdistribution hazard model accounting for the competing risks of death or LT, with predictive performance evaluated using the C-index and time-dependent area under the receiver operating characteristic curve (AUROC). The KACLiF-ACLF score integrated C-reactive protein, albumin, total bilirubin, international normalized ratio, and creatinine. In derivation, the competing-risk C-index (0.806 at 28 days; 0.791 at 90 days) significantly exceeded all eight comparators at 90 days, but not MELD or MELD-Na at 28 days. In external validation, it (0.892 and 0.889) significantly exceeded all comparators at both horizons. Time-dependent AUROCs at 28 days were 0.815 and 0.894, significantly exceeding all comparators at both horizons except MELD-Na at 28 days in derivation. Transported absolute risks were overpredicted, requiring recalibration. The model stratified patients into low-, intermediate-, and high-risk groups, correlating with cumulative ACLF incidence and transplant-free survival (P<0.001). The KACLiF-ACLF score discriminates ACLF development with high accuracy in external validation and supports risk stratification within a competing-risk framework. Recalibrated absolute risks require independent validation before clinical implementation.
中文摘要:当未纳入肝移植或无急性慢性肝衰竭死亡等竞争事件的危险度时,急性慢性肝衰竭的绝对风险可能被高估。我们开发并验证了一种整合系统性炎症的新型竞争风险模型以预测急性慢性肝衰竭的发生。推导队列来自前瞻性多中心韩国急性慢性肝衰竭队列,包含1,146名肝硬化急性失代偿患者。外部验证使用了包含1,104名患者的回顾性队列。本研究遵循TRIPOD+AI报告指南,应用了Fine-Gray亚分布风险模型以考虑死亡或肝移植的竞争风险,并使用C指数和时间依赖性受试者工作特征曲线下面积评估预测性能。KACLiF-ACLF评分整合了C反应蛋白、白蛋白、总胆红素、国际标准化比值和肌酐。在推导阶段,竞争风险C指数在28天为0.806,90天为0.791,在90天时显著优于所有八个比较模型,但在28天时未优于MELD或MELD-Na。在外部验证中,该评分在两个时间点的预测性能均显著优于所有比较模型。28天的时间依赖性AUROC分别为0.815和0.894,在推导阶段除28天时的MELD-Na外,显著优于所有比较模型。运输后的绝对风险被高估,需要重新校准。该模型将患者分为低、中、高风险组,与累积急性慢性肝衰竭发病率和无移植生存率相关(P<0.001)。KACLiF-ACLF评分在外部验证中以高精度区分急性慢性肝衰竭的发生,并支持在竞争风险框架内的风险分层。重新校准后的绝对风险需经独立验证方可用于临床实施。

3肝病/肝硬化 (2篇)

基础研究 (2篇)

IEEE transactions on cybernetics IF 11.3 2026-11-17 PMID: 43043736
This article addresses an asymmetric multiagent pursuit-evasion (MPE) differential gaming scenario, where pursuers, subject to the presence of external disturbances and unknown dynamics, aim to collaboratively intercept escaping evaders. The core technical challenge lies in designing a distributed optimal gaming protocol for such incomplete-information MPE games in an adversarial environment while guaranteeing the attainment of the Nash equilibrium. To address this problem, a model-based differential gaming framework is presented to eliminate the coupled terms in the associated Hamilton-Jacobi-Isaacs (HJI) equations and accordingly derive a distributed Nash equilibrium solution for multiagent systems (MASs). To dispense with prior knowledge of the pursuers' dynamics, a data-driven off-policy reinforcement learning (RL) algorithm is devised to learn the pursuers' optimal strategies online. Finally, simulation results are elaborated to validate the effectiveness of the proposed gaming strategy.
中文摘要:本文解决了一个不对称多智能体追逐-逃逸(MPE)微分博弈场景,其中追捕者受到外部干扰和未知动力学的影响,旨在协同拦截逃跑的逃逸者。核心技术挑战在于为这种对抗环境下的不完全信息MPE游戏设计一个分布式最优博弈协议,同时保证纳什均衡的实现。为解决这一问题,提出了一种基于模型的微分博弈框架,以消除关联的哈密顿-雅可比-艾萨克斯(HJI)方程中的耦合项,从而推导出多智能体系统(MASs)的分布式纳什均衡解。为了摆脱对追捕者动力学先验知识的依赖,设计了一种数据驱动的离线策略强化学习(RL)算法,以在线学习追捕者的最优策略。最后,通过详细的仿真结果验证了所提出博弈策略的有效性。
Water research IF 12.8 2026-11-14 PMID: 43057034
Nature-Based Systems are a critical approach to water management in urban watersheds. Assessing the effectiveness of such sustainable water management schemes depends fundamentally on sufficient and reliable water quality data. However, existing sparse monitoring networks lack continuous and reliable observation records, failing to meet the data requirements for monitoring spatiotemporal variations in water quality. Moreover, most conventional reconstruction methods are purely data-driven and lack the integration of hydrological knowledge, which hampers their capability to handle sparse observations in urban watersheds. To overcome these limitations, this paper proposes a deep learning-based spatiotemporal reconstruction framework for water-quality and hydrometeorological data. The framework first reconstructs missing hydrometeorological driving sequences. Subsequently, it leverages the reconstructed hydrological sequences to guide the reconstruction of water quality data, transforming sparse 4-hourly observations into complete hourly series. Finally, a probabilistic forecasting module is built upon the high-resolution reconstructed series, outputting Gaussian predictive means and standard deviations to quantify uncertainty and estimate the probability of exceeding water quality standards. The method is validated using field monitoring data from six stations in the Huaxi River watershed, Chongqing. Experimental results indicate that the reconstructed hourly water quality series outperform the original 4-hourly data in capturing pollutant concentration variability, with Nash-Sutcliffe efficiency improvements ranging from 0.18 to 0.57. These results demonstrate that the framework serves short-term probabilistic forecasting and early warning of water quality standard exceedances, providing timely data support for pollution risk management in urban watersheds. The code that supports the findings of this study is openly available in the HG-STGNN repository on GitHub at https://github.com/Indig0Cat/HG-STGNN.
中文摘要:基于自然的系统是城市流域水资源管理的关键方法。评估此类可持续水管理方案的有效性,根本上依赖于充足且可靠的水质数据。然而,现有的稀疏监测网络缺乏连续可靠的观测记录,无法满足水质时空变化监测的数据需求。此外,大多数传统重建方法纯粹基于数据驱动,缺乏水文知识的整合,这限制了其在处理城市流域稀疏观测数据方面的能力。为克服这些局限性,本文提出了一种基于深度学习的水质和水文气象数据时空重建框架。该框架首先重建缺失的水文气象驱动序列。随后,利用重建的水文序列指导水质数据的重建,将稀疏的4小时观测值转化为完整的 hourly 时间序列。最后,基于高分辨率重建序列构建概率预测模块,输出高斯预测均值和标准差以量化不确定性并估计超标概率。该方法使用重庆华溪河流域六个站点的现场监测数据进行了验证。实验结果表明,重建的小时级水质系列在捕捉污染物浓度变异性方面优于原始4小时数据,纳什-萨克利夫效率提升了0.18至0.57。这些结果证明该框架服务于短期概率预测和水质标准超标的早期预警,为城市流域的污染风险管理提供及时的数据支持。支持本研究发现的代码已在GitHub上的HG-STGNN存储库中公开,链接为https://github.com/Indig0Cat/HG-STGNN。

4NAFLD/NASH/代谢肝病 (2篇)

临床研究 (1篇)

Clinical and molecular hepatology IF 21.7 2026-11-17 PMID: 43041053
Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH) impose a rapidly increasing hepatic and cardiometabolic burden worldwide and in Korea. Following the phase 3 ESSENCE trial, which demonstrated the histological efficacy of semaglutide in noncirrhotic MASH with fibrosis, practical guidance for routine clinical care is needed. The Korean Association for the Study of the Liver developed this expert consensus statement on semaglutide treatment in MASH. Using the RAND/UCLA Appropriateness Method, a 15-member expert panel rated 98 clinical scenarios covering patient selection, dosing, response assessment, adverse event management, and metabolic comorbidities over two rating rounds with a structured panel discussion. Semaglutide is primarily intended for patients with noncirrhotic MASH and stage 2-3 fibrosis. Eligibility should be assessed using a two-step strategy of age-adjusted Fibrosis-4 index screening followed by vibration-controlled transient elastography (VCTE). A VCTE-derived liver stiffness measurement (LSM) of 10-15 kPa defines the preferred treatment range; 15-20 kPa is acceptable when cirrhosis and portal hypertension are excluded, whereas 8-10 kPa requires repeat VCTE, magnetic resonance elastography (eligible range, 3.1-4.4 kPa), or liver biopsy. Semaglutide is initiated at 0.25 mg once weekly and escalated every 4 weeks to a target maintenance dose of 2.4 mg. Response should be assessed with noninvasive tests after at least 18 months; a ≥30% reduction in VCTE-derived LSM suggests response. This consensus provides a structured framework for semaglutide use in MASH, integrated with management of obesity, type 2 diabetes, cardiovascular risk, and chronic kidney disease.
中文摘要:代谢功能障碍相关脂肪性肝病及代谢功能障碍相关脂肪性肝炎(MASH)在全球及韩国造成日益增加的肝脏和心血管代谢负担。在证明司美格鲁肽对伴有纤维化的非肝硬化MASH具有组织学疗效的III期ESSENCE试验之后,临床常规护理需要实践指导。韩国肝脏研究协会制定了关于MASH治疗中司美格鲁肽应用的专家共识声明。采用RAND/UCLA适宜性方法,由15名专家组成的专家组通过两轮评分及结构化小组讨论,对涵盖患者选择、剂量调整、疗效评估、不良事件管理及代谢合并症在内的98个临床场景进行了评级。司美格鲁肽主要适用于伴有2至3期纤维化的非肝硬化MASH患者。资格评估应采用两步策略:首先进行年龄调整的Fibrosis-4指数筛查,随后进行振动控制瞬时弹性成像(VCTE)。VCTE衍生的肝脏硬度测量值(LSM)为10至15 kPa定义为首选治疗范围;在排除肝硬化和门脉高压的情况下,15至20 kPa也可接受,而8至10 kPa则需重复VCTE、磁共振弹性成像(适用范围为3.1至4.4 kPa)或肝活检。司美格鲁肽起始剂量为每周一次0.25 mg,每4周递增一次,目标维持剂量为2.4 mg。疗效应在至少18个月后通过无创测试进行评估;VCTE衍生的LSM降低≥30%提示治疗有效。该共识为MASH中司美格鲁肽的使用提供了结构化框架,并与肥胖、2型糖尿病、心血管风险及慢性肾脏病的管理相整合。

基础研究 (1篇)

Autophagy IF 18.6 2026-11-16 PMID: 42946691
Excess lipid accumulation and a sedentary lifestyle are associated with metabolic dysfunction-associated fatty liver disease (MAFLD), but the causal mechanisms and preventive methods are not fully understood. Macroautophagy/autophagy is a lysosomal degradation pathway robustly induced by exercise and plays a key role in lipid metabolism. Understanding the mechanisms by which exercise activates autophagy and elicits metabolic benefits in the liver will provide important insights into the pathogenesis of MAFLD. Here, we discovered negative correlations between expression and lactylation of WDR41 (WD repeat domain 41) and pathogenesis of a series of human hepatic metabolic diseases. We found that WDR41 was a pro-autophagy protein that underwent lactylation in response to autophagy-inducing conditions, such as exercise. WDR41 was lactylated at lysine 319 (K319), a modification facilitated by LDHA (lactate dehydrogenase A) upon autophagy induction, and delactylated by SIRT2 (sirtuin 2). Lactylated WDR41 promoted autophagy initiation by directly interacting with the autophagy proteins ATG13 (autophagy related 13) and RB1CC1/FIP200 (RB1 inducible coiled-coil 1) and driving the ULK1 (unc-51 like autophagy activating kinase 1) complex assembly. Physiologically, WDR41 and WDR41K319 lactylation, were important for exercise-induced improvements in insulin sensitivity and lipid metabolism against excess lipid accumulation in the liver. Thus, we demonstrated that WDR41 lactylation at K319 is an important regulatory mechanism by which exercise regulates autophagy and hepatic glucose and lipid metabolism.Abbreviations: AV: adeno-associated virus; ALS: amyotrophic lateral sclerosis; ALT: alanine aminotransferase; AMPK: AMP-activated protein kinase; ANOVA: analysis of variance; AST: aspartate aminotransferase; ATG13: autophagy related 13; BECN1: beclin 1; C9orf72: C9orf72-SMCR8 complex subunit; cDNA: complementary DNA; co-IP: co-immunoprecipitation; CQ: chloroquine; CRISPR: clustered regularly interspaced short palindromic repeats; EBSS: Earle's balanced salt solution; EE: energy expenditure; FN1/fibronectin: fibronectin 1; FTD: frontotemporal dementia; GAP: GTPase-activating protein; GEF: guanine nucleotide exchange factor; GFP: green fluorescent protein; gRNA: guide RNA; GST: glutathione S-transferase; GTT: glucose tolerance test; H&E: hematoxylin and eosin; HDAC: histone deacetylase; HFD: high-fat diet; i.p.: intraperitoneal; IP: immunoprecipitation; ITT: insulin tolerance test; KO: knockout; LC-MS/MS: liquid chromatography-tandem mass spectrometry; LDHA: lactate dehydrogenase A; MAFLD: metabolic dysfunction-associated fatty liver disease; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MASH: metabolic dysfunction-associated steatohepatitis; mRFP: monomeric red fluorescent protein; MS: mass spectrometry; MS/MS: tandem mass spectrometry; MTOR: mechanistic target of rapamycin kinase; NAS: NAFLD activity score; PBS: phosphate-buffered saline; PCR: polymerase chain reaction; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PTT: pyruvate tolerance test; PVDF: polyvinylidene fluoride; RB1CC1/FIP200: RB1 inducible coiled-coil 1; RD: regular diet; RER: respiratory exchange ratio; SDS: sodium dodecyl sulfate; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SEM: standard error of the mean; siRNA: small interfering RNA; SIRT2: sirtuin 2; SMCR8: SMCR8-C9orf72 complex subunit; SQSTM1/p62: sequestosome 1; STING1: stimulator of interferon response cGAMP interactor 1; TBG: thyroxine-binding globulin; TC: total cholesterol; TG: triglyceride; ULK1: unc-51 like autophagy activating kinase 1; ULK2: unc-51 like autophagy activating kinase2; UN: untreated; VCO2: carbon dioxide production; VO2: oxygen consumption; WB: western blotting; WDR41: WD repeat domain 41; WT: wild type.
中文摘要:脂质过度积累和久坐生活方式与代谢功能障碍相关脂肪性肝病(MAFLD)有关,但其因果机制和预防方法尚未完全阐明。巨自噬/自噬是一种溶酶体降解途径,由运动强烈诱导并在脂质代谢中发挥关键作用。了解运动激活自噬并产生肝脏代谢益处的机制将为理解MAFLD的发病机理提供重要见解。本研究发现了WDR41(WD重复结构域蛋白41)的表达和乳酸化修饰与一系列人类肝脏代谢疾病的发病机制之间存在负相关关系。我们发现WDR41是一种促自噬蛋白,在运动等诱导自噬的条件下会发生乳酸化修饰。WDR41在第319位赖氨酸(K319)发生乳酸化,该修饰由LDHA(乳酸脱氢酶A)在自噬诱导时促进,并由SIRT2(sirtuin 2)去乳酸化。乳酸化的WDR41通过直接与自噬蛋白ATG13和RB1CC1/FIP200相互作用并驱动ULK1复合物组装来促进自噬起始。生理上,WDR41及其K319位点的乳酸化对于运动改善胰岛素敏感性和脂质代谢以对抗肝脏脂质过度积累至关重要。因此,我们证明了WDR41在K319位的乳酸化是运动调节自噬以及肝脏葡萄糖和脂质代谢的重要调控机制。

5肝炎(病毒性) (1篇)

基础研究 (1篇)

Journal of hepatology IF 40.1 2026-11-19 PMID: 43057525
HEV infection is an underappreciated differential diagnosis in patients presenting with acute hepatitis during immune checkpoint inhibitor (ICI) therapy. As T-cells are the key targets of ICIs, particularly through blockade of inhibitory immune checkpoints such as PD-1, this intervention is likely to influence the dynamics and differentiation fate of de novo primed virus-specific T-cells during primary HEV infection. We therefore aimed to examine how PD-1 blockade during primary HEV-infection influences expansion, contraction, and memory formation of virus-specific CD8+ T-cells. HEV-specific CD8 and CD4+ T-cells were analyzed by applying a reverse phenotyping approach combined with single-cell transcriptomics and TCR sequencing, as well as multiparameter flow cytometry with MHC class I tetramers. We characterized HEV-specific T-cell responses in patients receiving ICI and in untreated patients during acute-viremic infection and after viral clearance. Under ICI, de novo primed HEV-specific CD8+ T-cells showed enhanced clonal expansion, cytotoxicity, and terminal differentiation. Rather than transitioning into classical memory subsets, these cells retained a cytotoxic transcriptional program and acquired features of long-lived effector-like T-cells (LLEC). While HEV-specific T-cells remained detectable over > 2 years, their functional recall responsiveness declined in ICI-treated patients. Collectively, our findings demonstrate that PD-1 blockade during the formation of a primary immune response reshapes the fate of the antiviral CD8+ T-cell pool, favoring terminally differentiated effector states over conventional memory formation, with potential implications for viral infections, vaccination, and immunotherapeutic strategies. Our study represents the first demonstration in a human model that PD-1 blockade during primary antigen exposure reshapes antiviral CD8+ T-cell effector formation and memory differentiation. By identifying PD-1 signaling during a primary immune response as a regulator of antiviral CD8+ T-cell fate, our findings establish a conceptual framework for understanding how immune checkpoint blockade influences the development of primary antiviral T-cell responses, with implications for viral infections, vaccination, and immunotherapeutic strategies.
中文摘要:在免疫检查点抑制剂治疗期间,HEV感染是急性肝炎患者中一个被低估的鉴别诊断。由于T细胞是ICIs的主要靶点,特别是通过阻断PD-1等抑制性免疫检查点,这种干预可能会影响原发HEV感染期间新生病毒特异性T细胞的动态变化和分化命运。因此,我们旨在研究原发HEV感染期间的PD-1阻断如何影响病毒特异性CD8+ T细胞的扩增、收缩和记忆形成。我们采用反向表型分析方法结合单细胞转录组学和TCR测序,以及使用MHC I类四聚体的多参数流式细胞术,分析了HEV特异性CD8和CD4+ T细胞。我们在接受ICI治疗的患者和未治疗患者在急性病毒血症感染期间及病毒清除后,表征了HEV特异性T细胞反应。在ICI作用下,新生HEV特异性CD8+ T细胞表现出增强的克隆扩增、细胞毒性和终末分化。这些细胞并未转化为经典记忆亚群,而是保留了细胞毒性转录程序并获得了长寿命效应样T细胞(LLEC)的特征。尽管HEV特异性T细胞在超过2年的时间里仍可检测到,但其功能回忆反应性在ICI治疗患者中下降。综上所述,我们的研究结果表明,在原发免疫反应形成期间的PD-1阻断重塑了抗病毒CD8+ T细胞池的命运,倾向于终末分化效应状态而非传统记忆形成,这对病毒感染、疫苗接种和免疫治疗策略具有潜在意义。本研究首次在人类模型中证明,原发抗原暴露期间的PD-1阻断重塑了抗病毒CD8+ T细胞的效应形成和记忆分化。通过将原发免疫反应期间的PD-1信号识别为调节抗病毒CD8+ T细胞命运的关键因素,我们的研究建立了理解免疫检查点阻断如何影响原发抗病毒T细胞反应发展的概念框架,这对病毒感染、疫苗接种和免疫治疗策略具有启示意义。

6内镜/ESD/ERCP (1篇)

临床研究 (1篇)

Endoscopy IF 11.8 2026-11-19 PMID: 43057246
The European Society of Gastrointestinal Endoscopy (ESGE) published its first Position Statement on digestive conditions that do not require endoscopy in 2020. Since then, multiple ESGE guidelines have expanded recommendations that promote appropriate indications, de-escalation of surveillance, and evidence-based avoidance of low value procedures. In parallel, avoiding unnecessary endoscopy has emerged as a major strategy for reducing the environmental burden of gastrointestinal endoscopy. This updated Position Statement consolidates such ESGE recommendations into a practical framework defining when endoscopy is not required. This Position Statement is based exclusively on recommendations developed or endorsed by ESGE. Recommendations from ESGE Guidelines and Position Statements published in Endoscopy were systematically reviewed and synthesized. Positive recommendations advocating alternative management strategies were reformulated, where appropriate, into explicit "do not perform endoscopy" statements without modifying the underlying evidence or recommendation strength. The resulting document provides a clinically oriented synthesis rather than new guideline recommendations. Recommendations covering upper gastrointestinal endoscopy, colonoscopy, endoscopic ultrasound, endoscopic retrograde cholangiopancreatography, capsule endoscopy, and therapeutic endoscopy were identified. Across these modalities, four overarching scenarios emerged in which endoscopy is not required: screening when endoscopy does not meaningfully prevent disease incidence or improve relevant outcomes; surveillance when repeat endoscopy provides no additional benefit beyond an adequate index examination or when expected benefit is limited by age, co-morbidity, or life expectancy; diagnostic endoscopy when validated noninvasive strategies provide sufficient information or when endoscopic findings are unlikely to change management; and therapeutic endoscopy when intervention does not improve clinically relevant outcomes compared with conservative or alternative management. Additional principles include avoiding redundant investigations and unnecessary repetition of adequately performed procedures. Together, these recommendations provide a framework for reducing low value endoscopy while limiting patient burden, healthcare resource use, and environmental impact. An appropriate indication is the cornerstone of high quality endoscopy and the primary driver of sustainable endoscopic practice. Endoscopy should be avoided when it does not provide meaningful additional benefit in screening, surveillance, diagnosis, or therapy. Applying these principles can improve patient safety, optimize healthcare resources, and reduce the environmental footprint of endoscopy. This updated ESGE Position Statement provides an evidence-based framework for high value, patient-centered, and sustainable endoscopic practice.
中文摘要:欧洲胃肠内镜学会(ESGE)于2020年首次发布关于无需内镜检查的消化系统疾病的立场声明。此后,多项ESGE指南扩展了推荐意见,以促进合理适应症、降低监测强度并基于证据避免低价值操作。同时,避免不必要的内镜检查已成为减少胃肠道内镜环境负担的主要策略。本更新版立场声明将此类ESGE推荐整合为定义何时不需要内镜检查的实用框架。该声明仅基于ESGE制定或认可的推荐意见。系统回顾并综合了发表在Endoscopy期刊上的ESGE指南和立场声明中的推荐意见,并将倡导替代管理策略的正面推荐在适当情况下重构为明确的“不执行内镜检查”陈述,且不修改底层证据或推荐强度。 resulting document provides a clinically oriented synthesis rather than new guideline recommendations. 识别出涵盖上消化道内镜、结肠镜、超声内镜、内镜逆行胰胆管造影、胶囊内镜和治疗内镜的建议。在这些技术中,出现了四种无需内镜检查的总体场景:当内镜检查不能有意义地预防疾病发生或改善相关结局时的筛查;当重复内镜检查在充分的首次检查基础上不提供额外益处,或因年龄、合并症或预期寿命限制而获益有限时的监测;当经过验证的非侵入性策略提供足够信息或内镜发现不太可能改变管理方案时的诊断内镜;以及当干预措施相比保守或替代管理未能改善临床相关结局时的治疗内镜。其他原则包括避免冗余检查和重复进行已充分执行的操作。这些推荐共同构成了减少低价值内镜检查、限制患者负担、医疗资源使用及环境影响的框架。合适的适应症是高质量内镜的基石,也是可持续内镜实践的主要驱动力。当内镜在筛查、监测、诊断或治疗中不能提供有意义的额外益处时,应避免使用。应用这些原则可提高患者安全、优化医疗资源并减少内镜的环境足迹。本更新的ESGE立场声明为高价值、以患者为中心且可持续的内镜实践提供了基于证据的框架。

7肝炎(病毒性/自免) (1篇)

临床研究 (1篇)

Clinical and molecular hepatology IF 21.7 2026-11-17 PMID: 43041061
Marked hepatitis flares, defined in this study as alanine aminotransferase (ALT) elevations exceeding five times the upper limit of normal, occur in acute and chronic liver diseases and may be associated with severe liver injury. However, the circulating immune profiles associated with the extent of liver injury remain incompletely characterized. We aimed to characterize circulating CD8 T cell phenotypes and soluble immune mediators during hepatitis flares across different etiologies. In a retrospective cross-sectional analysis, soluble immune mediators and circulating CD8 T cell phenotypes were analyzed in 71 patients with hepatitis flares using Luminex assays and spectral flow cytometry. Exploratory functional experiments included in vitro PBMC stimulation and co-culture of sorted CD8 T cell subsets with Huh7 hepatoma cells. A public HBV single-cell RNA-sequencing dataset was reanalyzed to contextualize circulating and intrahepatic CD8 T cell states. Circulating CXCR6+PD-1+ CD8 T cell frequencies were associated with biochemical markers of liver injury and dysfunction. HLA-DR expression within this subset was associated with the hepatocyte injury index, bilirubin levels, and plasma CXCL10 (IP-10) concentrations. Activation-marker and granzyme expression differed across flare etiologies, and CXCR6+PD-1+ CD8 T cells retained inducible effector responses following cytokine stimulation. Reanalysis of a public HBV scRNA-seq dataset identified a liver-enriched CXCR6/PDCD1/HLA-DRAhi GZMKhi CD8 T cell state. Circulating CXCR6+PD-1+ CD8 T cells represent an activation-associated population that correlates with biochemical liver injury during hepatitis flares and retains inducible effector capacity. Whether these cells contribute to or reflect ongoing liver inflammation remains to be determined.
中文摘要:显著性肝炎发作定义为丙氨酸氨基转移酶升高超过正常上限五倍,见于急慢性肝病且可能伴随严重肝损伤。目前相关循环免疫特征尚不明确。本研究旨在表征不同病因肝炎发作期间的循环CD8 T细胞表型及可溶性免疫介质。在回顾性横断面分析中,利用Luminex检测和光谱流式细胞术分析了71例肝炎发作患者的数据。探索性功能实验包括体外PBMC刺激、分选CD8 T细胞亚群与Huh7肝癌细胞的共培养,并重新分析了公共HBV单细胞RNA测序数据集以阐明循环及肝内CD8 T细胞状态。结果显示,循环CXCR6+PD-1+ CD8 T细胞频率与肝损伤及功能障碍的生物标志物相关。该亚群的HLA-DR表达与肝细胞损伤指数、胆红素水平及血浆CXCL10浓度相关。激活标志物和颗粒酶表达在不同发作病因间存在差异,且CXCR6+PD-1+ CD8 T细胞在细胞因子刺激后仍保留可诱导的效应反应。公共HBV scRNA-seq数据集重新分析鉴定出一种富含肝脏的CXCR6/PDCD1/HLA-DRAhi GZMKhi CD8 T细胞状态。循环CXCR6+PD-1+ CD8 T细胞代表一种与肝炎发作期间生化肝损伤相关的激活相关群体,并保留可诱导的效应能力。这些细胞是促进还是反映持续肝炎症仍有待确定。

8病毒性肝炎 (1篇)

基础研究 (1篇)

Clinical microbiology reviews IF 20.7 2026-11-16 PMID: 43037422
SUMMARYHuman pathogenic viruses, including HIV, hepatitis B virus, and hepatitis C virus, as well as recent global outbreaks and pandemics caused by RNA viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV; 2002-2003), Middle East respiratory syndrome-CoV (2012-2015 and 2019), and SARS-CoV-2 (2019-2023), have resulted in a significant loss of life. The development of antiviral drugs has provided therapeutic options, enabling more effective treatment. With the discovery of idoxuridine, the first antiviral nucleoside approved by the U.S. Food and Drug Administration in 1963, a series of antiviral nucleosides and nucleotides has been approved worldwide over the following 60 years. These drugs, with the potential to interfere with DNA/RNA synthesis, demonstrated unique therapeutic mechanisms. In this review, we focus on adenine nucleoside and nucleotide analogs as antiviral drugs, summarizing their antiviral mechanisms across the viral life cycle, representative potent small-molecule agents with diverse scaffolds, current clinical development, and combination therapies, as well as modification strategies based on the adenosine scaffold developed over the past 60 years. In addition to the development of new antiviral agents, some adenine nucleoside and nucleotide analogs have been repurposed for new indications, and some of them, such as remdesivir, exhibit broad-spectrum antiviral activity. Through the summary of past achievements, current challenges, and available opportunities in both biology and chemistry, we hope to inspire the future development of antiviral nucleosides/nucleotides.
中文摘要:人类致病病毒包括HIV、乙肝病毒和丙肝病毒,以及由SARS-CoV(2002-2003年)、MERS-CoV(2012-2015年和2019年)和SARS-CoV-2(2019-2023年)等RNA病毒引起的近期全球暴发和大流行,造成了巨大的人员伤亡。抗病毒药物的开发提供了治疗选择,使治疗更加有效。自1963年美国FDA批准第一种抗病毒核苷类药物碘苷以来,过去60年间全球批准了一系列抗病毒核苷和核苷酸类药物。这些药物具有干扰DNA/RNA合成的潜力,展现了独特的治疗机制。本综述聚焦于作为抗病毒药物的腺嘌呤核苷和核苷酸类似物,总结了它们在病毒生命周期中的抗病毒机制、具有不同骨架的代表性强效小分子药物、当前的临床开发进展及联合疗法,以及过去60年间基于腺苷骨架开发的修饰策略。除了新型抗病毒药物的开发外,部分腺嘌呤核苷和核苷酸类似物已被重新定位用于新适应症,其中一些如瑞德西韦表现出广谱抗病毒活性。通过对过去成就、当前挑战以及在生物学和化学领域现有机遇的总结,我们期望激发未来抗病毒核苷/核苷酸类药物的研发灵感。

9消化道早癌筛查 (1篇)

基础研究 (1篇)

Biomarker research IF 14.6 2026-11-15 PMID: 43035807
Reliable biomarkers for cancer early detection, prognostic stratification, recurrence surveillance, and treatment-response prediction remain clinically insufficient. tRNA-derived small RNAs (tsRNAs) are abundant, structurally compact, and recurrently dysregulated in malignancy, and have been widely proposed as liquid-biopsy analytes. Their biogenesis, mechanisms, and therapeutic prospects have been reviewed extensively. What has not been assessed is whether the reported clinical evidence supports the claims attached to it, and that is the question this review addresses. We appraise published circulating tsRNA studies against four criteria that govern progression toward clinical use: analytical validity, cohort design and comparator choice, independent validation, and demonstrated incremental clinical utility. Biology is summarized only where it bears on measurement-the distinct enzymatic routes that generate tRNA-derived fragments and tRNA halves, the terminal chemistries they impose, the modifications that bias library construction, and the extracellular biology that determines what is actually quantified in blood. Candidates are then re-classified by intended use and graded by validation level in a structured evidence table reporting cohort size, comparator group, platform, normalization, diagnostic performance, and validation status. Most candidates rest on single-center retrospective case-control comparisons against healthy donors. Detection in stage I disease has been conflated with early detection, and postoperative decline with rcrrence monitoring. Disease specificity is frequently untested, notably for glycine-GCC-derived fragments, which also rise in active inflammatory bowel disease. No circulating tsRNA has yet demonstrated incremental clinical value in a prospectively validated setting. tsRNAs remain a biologically compelling and analytically tractable biomarker reservoir. Realizing that potential will require standardized pre-analytics, clinically relevant comparators, transfer to analytically validated targeted assays, and independent multicenter validation. We provide a minimum reporting checklist and a nomenclature cross-walk to support this.
中文摘要:可靠的癌症早期检测、预后分层、复发监测及治疗反应预测生物标志物在临床上仍显不足。tRNA衍生小RNA(tsRNAs)丰度高、结构紧凑且在恶性肿瘤中反复失调,已被广泛提议作为液体活检分析物。其生物发生机制、作用机理及治疗前景已有大量综述。然而,现有报道的临床证据是否支持相关主张尚未得到评估,这正是本综述旨在解决的问题。我们依据四项决定临床应用进展的标准对已发表的循环tsRNA研究进行评估:分析有效性、队列设计与比较组选择、独立验证以及明确的增量临床效用。仅在涉及测量时总结生物学背景,包括生成tRNA衍生片段和tRNA半分子的独特酶促途径、它们施加的末端化学修饰、影响文库构建的修饰以及决定血液中实际定量内容的细胞外生物学特性。随后根据预期用途对候选分子重新分类,并在结构化证据表中按验证水平分级,报告队列规模、比较组、平台、标准化方法、诊断性能及验证状态。大多数候选分子仅基于单中心回顾性病例对照研究,与健康供体进行比较。I期疾病的检测常被混淆为早期检测,术后下降被等同于复发监测。疾病特异性经常未经测试,特别是甘氨酸-GCC衍生片段,它们在活动性炎症性肠病中也会升高。在前瞻性验证环境中,尚无循环tsRNA证明具有增量临床价值。tsRNAs仍然是生物学上引人入胜且分析上可行的生物标志物库。实现这一潜力需要标准化的前处理、临床相关的比较组、转移至分析验证的目标检测 assay 以及独立的多中心验证。我们提供了一份最低限度报告清单和命名法对照表以支持这一目标。

10胰腺癌 (1篇)

临床研究 (1篇)

Biosensors & bioelectronics IF 11.8 2026-11-14 PMID: 43044444
Pancreatic cancer (PC) is one of the most fatal malignancies worldwide, partly attributable to the lack of robust tools for clinical screening and diagnosis. Although liquid biopsy holds great promise for PC diagnosis, unified analysis of extracellular-vesicle, nucleic-acid, and protein biomarkers remains challenging because of their distinct analytical requirements and large differences in abundance. Here, we report a microscale size-encoded deterministic lateral displacement platform for unified analysis of heterogeneous liquid-biopsy biomarkers. By integrating aptamer recognition, microscale size encoding, Exonuclease III-mediated signal amplification, deterministic lateral displacement (DLD) microfluidics, and a self-developed vacuum-driven microfluidic imaging system, glypican-1-positive extracellular vesicles (GPC1+ EVs), microRNA-21 (miR-21), and carbohydrate antigen 19-9 (CA19-9) are encoded into microspheres of distinct sizes for simultaneous quantification directly from diluted serum within 1 h without complex preprocessing. Notably, GPC1+ EVs are directly analyzed without extracellular-vesicle isolation through a dual-aptamer recognition strategy that minimizes interference from soluble GPC1. The platform achieved detection limits of 3.23 × 105 particles mL-1 for GPC1+ EVs, 536 fM for miR-21, and 5.5 × 10-2 U mL-1 for CA19-9, providing sufficient analytical sensitivity for direct analysis of diluted serum samples. Clinical validation in 240 individuals demonstrated robust diagnostic performance, with a three-biomarker support vector machine model achieving area under the receiver operating characteristic curve values of 0.9822 for PC versus healthy controls and 0.9782 for PC versus pancreatitis in an independent test cohort. This work establishes a microscale size-encoding strategy that extends DLD microfluidics from microscale particle analysis to unified analysis of heterogeneous liquid-biopsy biomarkers, providing a general framework for multidimensional cancer diagnostics.
中文摘要:胰腺癌是世界上最致命的恶性肿瘤之一,部分原因在于缺乏用于临床筛查和诊断的可靠工具。尽管液体活检在胰腺癌诊断方面前景广阔,但由于不同生物标志物的分析要求各异且丰度差异巨大,统一分析细胞外囊泡、核酸和蛋白质生物标志物仍具挑战性。本研究报道了一种基于微尺度尺寸编码的确定性侧向位移平台,用于统一分析异质性液体活检生物标志物。通过整合适配体识别、微尺度尺寸编码、外切酶III介导的信号放大、确定性侧向位移微流控技术以及自主研发的真空驱动微流控成像系统,将糖蛋白1阳性细胞外囊泡、微小RNA-21和碳水化合物抗原19-9编码为不同尺寸的微球,从而在稀释血清中直接进行同时定量分析,整个过程无需复杂预处理且耗时仅1小时。值得注意的是,该研究采用双适配体识别策略直接分析糖蛋白1阳性细胞外囊泡,最大限度地减少了可溶性糖蛋白1的干扰。该平台对糖蛋白1阳性细胞外囊泡、微小RNA-21和碳水化合物抗原19-9的检测限分别为3.23×10^5颗粒/mL、536 fM和5.5×10^-2 U/mL,为直接分析稀释血清样本提供了足够的分析灵敏度。在240名受试者中的临床验证表明其具有稳健的诊断性能,在三生物标志物支持向量机模型中,独立测试队列对胰腺癌与健康对照以及胰腺癌与胰腺炎的受试者工作特征曲线下面积值分别为0.9822和0.9782。这项工作确立了一种微尺度尺寸编码策略,将确定性侧向位移微流控技术从微尺度颗粒分析扩展至异质性液体活检生物标志物的统一分析,为多维癌症诊断提供了一般性框架。

11其他 (2篇)

临床研究 (1篇)

Nature medicine IF 52.5 2026-11-19 PMID: 43058222
Immune effector cell-associated enterocolitis (IEC-EC) is a delayed toxicity of ciltacabtagene autoleucel. The US Multiple Myeloma Immunotherapy Consortium retrospectively adjudicated 54 suspected cases from 8 institutions: 41 were IEC-EC (31 confirmed by anti-camelid variable heavy-chain immunohistochemistry, 10 probable). Through September 2025, cumulative incidence was 3.0% (39 of 1,308 ciltacabtagene autoleucel recipients; 95% CI 2.1-4.1%); 12-month competing-risk incidence was 3.0% (95% CI 2.1-4.1%). Median symptom onset was 75 days after infusion. Grade ≥3 diarrhea occurred in 85% (34 of 40 with diarrhea); 73% (30 of 41) required parenteral nutrition. Despite normal upper endoscopy in 41% (9 of 22), duodenal biopsies showed villous blunting, apoptotic bodies and a dense cytotoxic T cell infiltrate, CD4+ in 61% (19 of 31), CD8+ in 26% (8 of 31) and mixed in 13% (4 of 31). A dominant T cell clone was detected in 76% (13 of 17 tested). Delayed neurotoxicity co-occurred in 41% (17 of 41). At last follow-up, 32% (13 of 41) resolved, 27% (11 of 41) had ongoing symptoms and 41% (17 of 41) died with active IEC-EC. Combined biologic and T cell-directed therapy yielded the highest resolution (55%, 6 of 11) in small subgroups. IEC-EC is potentially fatal and requires systematic evaluation and early directed therapy.
中文摘要:免疫效应细胞相关肠结肠炎(IEC-EC)是西米卡巴仑自细胞输注的一种迟发性毒性。美国多发性骨髓瘤免疫治疗联盟对来自8个机构的54例疑似病例进行了回顾性判定,其中41例确诊为IEC-EC(31例经抗骆驼科重链可变区免疫组化确认,10例可能)。截至2025年9月,累积发生率为3.0%(1308名西米卡巴仑自细胞接受者中的39人;95%置信区间2.1-4.1%);12个月竞争风险发生率为3.0%(95%置信区间2.1-4.1%)。症状中位发作时间为输注后75天。85%(40例腹泻患者中的34例)出现3级及以上腹泻;73%(41例中的30例)需要肠外营养。尽管41%(22例中的9例)上消化道内镜正常,但十二指肠活检显示绒毛变平、凋亡小体和密集的细胞毒性T细胞浸润,其中CD4+占61%(31例中的19例),CD8+占26%(31例中的8例),混合型占13%(31例中的4例)。76%(17例检测者中的13例)检测到优势T细胞克隆。41%(41例中的17例)合并迟发性神经毒性。在最后一次随访时,32%(41例中的13例)缓解,27%(41例中的11例)仍有持续症状,41%(41例中的17例)死于活动性IEC-EC。在小型亚组中,联合生物制剂和T细胞靶向治疗实现了最高的缓解率(55%,11例中的6例)。IEC-EC具有潜在致命性,需要系统性评估和早期靶向治疗。

基础研究 (1篇)

Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42424996
Rapid and selective detection of viral pathogens is essential for effective disease surveillance and outbreak control. To meet this demand, thermo-responsive epitope-imprinted nanogels were integrated into a quartz crystal microbalance (QCM) platform for the selective detection of Hepatitis A virus (HAV) in real samples. Two HAV-derived epitopes (Epitope 2 and Epitope 3), identified by in-silico analysis, were employed as templates for the solid-phase synthesis of molecularly imprinted polymer nanogels (MIP-NGs). Successful nanogel formation was confirmed by Fourier-transform infrared (FTIR) spectroscopy, dynamic light scattering, and electrophoretic light scattering. The binding affinities of the imprinted nanogels were comparatively evaluated using surface plasmon resonance, yielding dissociation constants (KD) of 2.49 × 10-11 M and 5.07 × 10-13 M for Epitope-2 MIP-NGs and Epitope-3 MIP-NGs, respectively. Based on their superior affinity, Epitope-3 MIP-NGs were selected as recognition elements and immobilized onto the QCM sensor surface for mass-based virus detection. Two immobilization strategies were investigated: drop-casting and electrochemical deposition via cyclic voltammetry in the presence of o-aminophenol and graphene quantum dots. Sensor surface formation was verified by atomic force microscopy and contact angle measurements. HAV detection was performed at 38 °C, under conditions where nanogel collapse supports binding via epitope-specific cavities. Real-time QCM measurements revealed concentration-dependent frequency shifts corresponding to HAV binding, achieving a detection limit of 1.05 pM over a working concentration range of 1.33-85 pM. Selectivity was assessed using non-imprinted polymer nanogels yielding an imprinting factor of 1.9, while specificity was confirmed against other pathogenic viruses. Finally, successful HAV detection in human serum demonstrated the applicability of the sensing platform in complex biological matrices.
中文摘要:病毒病原体的快速选择性检测对于有效的疾病监测和疫情控制至关重要。为满足这一需求,将热响应表位印迹纳米凝胶集成到石英晶体微天平(QCM)平台中,用于在真实样本中选择性检测甲型肝炎病毒(HAV)。通过计算机模拟分析鉴定出两个源自HAV的表位(表位2和表位3),并将其作为模板用于分子印迹聚合物纳米凝胶(MIP-NGs)的固相合成。傅里叶变换红外光谱、动态光散射和电泳光散射证实了纳米凝胶的成功形成。利用表面等离子体共振技术比较评估了印迹纳米凝胶的结合亲和力,分别得到表位2 MIP-NGs和表位3 MIP-NGs的解离常数(KD)为2.49×10^-11 M和5.07×10^-13 M。基于其优异的亲和力,选择表位3 MIP-NGs作为识别元件并固定于QCM传感器表面以进行质量病毒检测。研究了两种固定化策略:滴铸法以及在邻氨基苯酚和石墨烯量子点存在下的循环伏安电化学沉积法。原子力显微镜和接触角测量验证了传感器表面的形成。HAV检测在38°C下进行,在此条件下纳米凝胶的塌陷通过表位特异性空腔支持结合。实时QCM测量揭示了与HAV结合相对应的浓度依赖性频率偏移,在1.33-85 pM的工作浓度范围内实现了1.05 pM的检测限。使用非印迹聚合物纳米凝胶评估选择性,得到印迹因子为1.9,并通过针对其他病原体病毒的测试确认了特异性。最后,在人血清中成功检测HAV证明了该传感平台在复杂生物基质中的适用性。